HRSA-25-046: AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF)
Closed
This grant is closed. A newer notice from the same program is forecast: AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF) (HRSA-27-077). Status: Expected deadline November 2, 2026. It is in our archive of Health Resources and Services Administration notices from 2024.
Health Resources and Services Administration offered grants to state and local governments. It expected to make about 25 awards worth $75.0 million in total. Applications closed on November 4, 2024.
From the official notice on Grants.gov, last changed September 30, 2024. Checked November 7, 2026.
- Total funding$75.0 million
- Expected awards25
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-27-077 | July 13, 2026 | Expected deadline November 2, 2026 | Forecast |
| HRSA-24-064 | July 20, 2023 | Closed October 24, 2023 | Closed |
| HRSA-23-056 | July 13, 2022 | Closed October 11, 2022 | Closed |
| HRSA-22-035 | July 26, 2021 | Closed October 25, 2021 | Closed |
Key dates
| Posted | September 3, 2024 |
|---|---|
| Deadline | November 4, 2024 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants are limited to states/territories that receive RWHAP Part B funding and need additional funding to:reduce or eliminate an existing ADAP waiting list,actively prevent the implementation of an ADAP waiting list,address a reduction in available resources to fund ADAP,address a current or projected increase in treatment needs aligned with ending the HIV epidemic in the U.S., and/oraddress other increases in the number of clients in the program due to new diagnosis, re-engagement in care, loss of income, and/or loss of health care coverage. Individuals are not eligible applicants under this NOFO.States/territories that do not currently meet one or more of the above criteria are not eligible to apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF). The Health Resources and Services Administration (HRSA), HIV/AIDS Bureau (HAB), Division of State HIV/AIDS Programs (DSHAP) administers this program. ADAP ERF awards are intended for states/territories that demonstrate the need for additional resources to address a reduction in available resources to fund ADAP. HRSA will base ADAP ERF awards upon your ability to successfully demonstrate need for additional funding. An external merit review panel (MRP) will evaluate this need based on criteria published in this notice of funding opportunity (NOFO), with priority given to addressing existing waiting lists. HRSA first funded the ADAP ERF initiative in August 2010, when numerous states/territories were experiencing ADAP waiting lists. At the time of this NOFO publication, there are no ADAP waiting lists. States/territories that establish a waiting list after the publication of this NOFO must report the waiting list to HRSA immediately and use funding awarded under this NOFO to remove clients from the waiting list. Previously, eligibility for this funding was limited to states/territories that had historically imposed waiting lists. HRSA continues to anticipate potential increases in clients in need of ADAP services due to reductions in program income or rebates, loss of health care coverage among people with HIV, and increased case finding. States/territories may use ERF funds to address current or projected increases in treatment needs aligned with ending the HIV epidemic in the U.S. or other increases in the number of clients in their ADAP.
Who has won HIV Care Formula Grants grants before
From fiscal 2021 to 2025, HIV Care Formula Grants (93.917) awarded $6.3 billion across 133 grant awards, an average of $47.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 3 | $742 million |
| Health Research, Inc. | New York | 2 | $663 million |
| Florida Department of Health | Florida | 3 | $643 million |
| Department of State Health Services | Texas | 3 | $636 million |
| State of Georgia Department of Public Health | Georgia | 3 | $369 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-077, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-25-046 still open?
No. It closed on November 4, 2024. A newer notice is forecast: HRSA-27-077, expected deadline November 2, 2026.
Who can apply for AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF)?
Health Resources and Services Administration accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF)?
Closed November 4, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $75.0 million in total across about 25 awards.
Who has won HIV Care Formula Grants grants before?
The largest recipients over five fiscal years were California Department of Public Health, Health Research, Inc., Florida Department of Health. The program made 133 awards worth $6.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)